Aytu BioPharma Inc. (AYTU)
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
📈 **POSITIVE** • Medium confidence analysis (67%) • Strong positive catalyst • High growth potential **Sentiment:** Positive (95%) **Content type:** General